Thromb Haemost 2023; 123(03): 362-365
DOI: 10.1055/s-0042-1760128
DOI: 10.1055/s-0042-1760128
Letter to the Editor
Direct Oral Anticoagulants or Vitamin K Antagonists after TAVR: Insights from the ENVISAGE-TAVI AF and ATLANTIS Trials
Federico Oliveri
1
Department of Molecular Medicine, Division of Cardiology, University of Pavia, Pavia,
Italy
,
Andrea Bongiorno
1
Department of Molecular Medicine, Division of Cardiology, University of Pavia, Pavia,
Italy
,
Lorenzo Tua
1
Department of Molecular Medicine, Division of Cardiology, University of Pavia, Pavia,
Italy
,
2
Interventional Cardiology, De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy
,
Alessandro Fasolino
1
Department of Molecular Medicine, Division of Cardiology, University of Pavia, Pavia,
Italy
,
Francesca Romana Gentile
1
Department of Molecular Medicine, Division of Cardiology, University of Pavia, Pavia,
Italy
,
Antonella Pepe
1
Department of Molecular Medicine, Division of Cardiology, University of Pavia, Pavia,
Italy
,
Marco Ferlini
3
Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
,
Stefano Ghio
3
Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
,
Sergio Leonardi
1
Department of Molecular Medicine, Division of Cardiology, University of Pavia, Pavia,
Italy
3
Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
› Author Affiliations